FrancophonIA/ELRC3.0 huggingface dataset:
English: • a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
Maltese: • storja ta' sindromu newrolettiku malinn (disturb perikoluż fis-sistema nervuża li normalment ikun ikkawżat minn mediċini antipsikotiċi) jew rabdomijoliżi (tkissir tal-fibri muskolari).
English: This is a summary of the European public assessment report (EPAR) for Corbilta.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Corbilta.
English: What are the risks associated with Corbilta?
Maltese: X'inhuma r-riskji assoċjati ma' Corbilta?
English: Entacapone has been authorised in the European Union (EU) as Comtess/Comtan since 1998.
Maltese: Entacapone ilu awtorizzat fl-Unjoni Ewropea (UE) mill-1998 bħala Comtess/Comtan.
English: Both carbidopa and entacapone block some of the enzymes that are involved in the breakdown of levodopa in the body: carbidopa blocks the enzyme dopa decarboxylase, and entacapone blocks the enzyme catechol-O-methyl transferase (COMT).
Maltese: Kemm carbidopa kif ukoll entacapone jimblukkaw xi wħud millenzimi li huma involuti fit-tkissir ta' levodopa fil-ġisem: karbidopa jimblokka l-enzima dopa decarboxylase, filwaqt li entacapone jimblokka l-enzima catechol-O-methyl transferase (COMT).
English: The company used some of the data from Comtess/Comtan (entacapone) to support the use of Corbilta and presented data from the published literature for the use of the combination of levodopa and carbidopa.
Maltese: Il-kumpanija użat xi dejta minn Comtess/Comtan (entacapone) biex issostni l-użu ta' Corbilta u ppreżentat dejta mid-dokumentazzjoni ppubblikata għall-użu tal-kombinazzjoni ta' levodopa u carbidopa.
English: The company that makes Stalevo has agreed that its scientific data can be used for Corbilta (‘informed consent').
Maltese: Il-kumpanija li tagħmel Stalevo qablet li d-dejta xjentifika tagħha tista' tintuża għal Corbilta (‘kunsens informat').
English: The most common side effects with Corbilta (seen in more than 1 patient in 10) are dyskinesia (uncontrollable movements), aggravated Parkinsonism (worsening of Parkinson's disease), nausea (feeling sick) and harmless urine discoloration.
Maltese: L-effetti sekondarji l-aktar komuni b'Corbilta (li dehru f'iżjed minn pazjent wieħed minn kull 10) huma diskineżija (movimenti bla kontroll), Parkinsoniżmu aggravat (aggravar tas-sintomi tal-marda ta' Parkinson), nawżja (tħossok ma tiflaħx) u telf fil-kulur tal-awrina li huwa bla ħsara.
English: A risk management plan has been developed to ensure that Corbilta is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Corbilta jintuża bl-aktar mod sigur possibbli.
English: The company carried out ‘bioequivalence' studies to show that taking Corbilta produces the same levels of levodopa, carbidopa and entacapone in the blood as taking separate tablets containing entacapone and the combination of levodopa and carbidopa.
Maltese: Il-kumpanija wettqet studji ta' ‘bijoekwivalenza' li juru li t-teħid ta' Corbilta jipproduċi l-istess livelli ta' levodopa, carbidopa u entacapone fid-demm bħat-teħid b'mod separat tal-pilloli li fihom entacapone u l-kombinazzjoni ta' levodopa u carbidopa.
English: This medicine is the same as Stalevo, which is already authorised in the European Union (EU).
Maltese: Din il-mediċina hija l-istess bħal Stalevo, li diġà hija awtorizzata fl-Unjoni Ewropea (UE).
English: Serious side effects which have been reported much less often include gastrointestinal haemorrhage (bleeding in the gut) and angioedema (swelling under the skin of face or limbs).
Maltese: Effetti sekondarji serji li ġew irrapportati ferm inqas komuni jinkludu emorraġija gastrointestinali (fsada fl-imsaren) u anġjoedema (nefħa taħt il-ġilda tal-wiċċ jew ir-riġlejn).
English: Corbilta must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant).
Maltese: Corbilta ma għandux jintuża flimkien ma' mediċini oħrajn li jagħmlu parti mill-grupp tal-'inibituri talmonoaminossidażi' (tip ta' antidepressiv).
English: Fluctuations happen when the effects of the medication wear off and symptoms re-emerge.
Maltese: Il-flutwazzjonijiet iseħħu meta l-effetti tal-mediċina ma jibqgħux jinħassu u s-sintomi jfeġġu mill-ġdid.
English: Corbilta is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘fluctuations' towards the end of the period between two doses of their medication.
Maltese: Corbilta jintuża f'pazjenti li jkunu qegħdin jiġu kkurati b'kombinazzjoni ta' levodopa u tal-inibitur ta' dopa decarboxylase (żewġ kuri standard għall-kura tal-marda ta' Parkinson) u li jkollhom ‘flutwazzjonijiet' lejn tmiem il-perjodu bejn żewġ dożi tal-kura tagħhom.
English: It is used to treat adults with Parkinson's disease (a progressive brain disorder that causes shaking, slow movement and muscle stiffness).
Maltese: Jintuża fil-kura tal-adulti bil-marda tal-Parkinson (disturb progressiv fil-moħħ li jikkawża rogħda, dewmien filmovimenti u ebusija tal-muskoli).
English: How is Corbilta used?
Maltese: Kif jaħdem Corbilta?
English: What measures are being taken to ensure the safe and effective use of Corbilta?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat użu sigur u effettiv ta' Corbilta?
English: This summary was last updated in 10-2014
Maltese: Is-sommarju ġie aġġornat l-aħħar fi: 10-2014.
English: EMA/479129/2010 EMEA/V/C/000076
Maltese: EMEA/V/C/000076
English: Advocate (imidacloprid / moxidectin)
Maltese: Advocate (imidacloprid / mossidektina)
English: Advocate received a marketing authorisation valid throughout the EU on 2 April 2003.
Maltese: Advocate ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-2 ta' April 2003.
English: Further information on Advocate can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/advocate.
Maltese: Aktar informazzjoni dwar Advocate tinstab fuq is-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/veterinary/EPAR/advocate.
English: What are the risks associated with Advocate?
Maltese: X'inhuma r-riskji assoċjati ma' Advocate?
English: This overview was last updated in June 2019.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Ġunju 2019.
English: Other information about Advocate
Maltese: Informazzjoni oħra dwar Advocate
English: Dogs and cats weighing less than 1 kg and ferrets weighing less than 0.8 kg should only be treated after special consideration by the veterinarian.
Maltese: Il-kura ta' klieb u qtates li jiżnu inqas minn 1 kg u ta' inmsa li jiżnu inqas minn 0.8 kg għandha ssir biss wara valutazzjoni speċjali mill-veterinarju.
English: It contains two active substances, imidacloprid and moxidectin.
Maltese: Fih żewġ sustanzi attivi, l-imidakloprid u l-mossidektina.
English: The effectiveness of Advocate against the specified parasites was investigated in laboratory studies in cats, ferrets and dogs.
Maltese: L-effikaċja ta' Advocate kontra l-parassiti speċifikati ġiet investigata fl-istudji fil-laboratorju fil-qtates, fl-inmsa u fil-klieb.
English: What benefits of Advocate have been shown in studies?
Maltese: X'inhuma l-benefiċċji ta' Advocate li ħarġu mill-istudji?
English: • for the treatment of skin diseases in dogs caused by parasitic mites (sarcoptic mange and demodicosis);
Maltese: • għall-kura tal-klieb li jbatu minn mard tal-ġilda kkawżat minn dud parassita (ġarab sarkoptiku u demodikożi);
English: • as part of treatment strategies for flea allergy dermatitis (an allergic reaction to flea bites) in cats and dogs;
Maltese: • bħala parti minn strateġija ta' kura għad-dermatite allerġika mill-briegħed (reazzjoni allerġika għall-gdim tal-briegħed) fil-klieb u l-qtates;
English: Advocate is a medicine used on cats, ferrets and dogs suffering from, or at risk from, mixed parasitic infections (caused by several different types of parasites):
Maltese: Advocate huwa mediċina li tintuża fil-qtates, fl-inmsa u fil-klieb li huma f'riskju ta' infezzjonijiet parassitarji mħallta (ikkawżati minn bosta tipi differenti ta' parassiti) jew li jbatu minnhom:
English: People with a known sensitivity to benzyl alcohol, imidacloprid or moxidectin should administer the product with caution.
Maltese: Nies b'sensittività magħrufa għal alkoħol benżiliku, l-imidakloprid jew il-moksidektin għandhom jagħtu l-prodott b'kawtela.
English: Advocate is available as a spot-on solution in pre-filled pipettes (small plastic droppers), and comes in different strengths and pack sizes, depending on whether it is for use on cats, ferrets, or dogs, and on the size of the animal being treated.
Maltese: Advocate huwa disponibbli bħala soluzzjoni għal użu lokalizzat u f'pipetti mimlija minn qabel (pipetti żgħar tal-plastik) u jiġi f'dożaġġi u f'pakketti ta' daqs differenti, skont jekk hux se jintuża fuq il-qtates, l-inmsa jew fuq il-klieb u skont id-daqs tal-annimal li jkun qed jiġi kkurat.
English: Advocate should not be used in kittens under 9 weeks of age or in puppies under 7 weeks of age.
Maltese: Advocate m'għandux jintuża fi qtates żgħar ta' inqas minn 9 ġimgħat jew fi ġriewi ta' inqas minn 7 ġimgħat.
English: • for the prevention of heartworm disease (infection with Dirofilaria immitis) in cats, ferrets and dogs;
Maltese: • għall-prevenzjoni ta' mard tad-dud fil-qalb (heartworm) (infezzjoni bid-Dirofilaria immitis) fil qtates, fl-inmsa u fil-klieb;
English: If a cat or dog licks the application area, it might salivate for a short period and might show signs such as a lack of muscular coordination, shaking, abnormal breathing and/or vomiting.
Maltese: Jekk qattus jew kelb jilgħaq il-post fejn ġie applikat il-prodott, jista' jibda jbeżlaq ħafna għal ftit żmien u mbagħad jista' juri sinjali bħal nuqqas ta' koordinament muskolari, rogħda, nifsijiet anomali u/jew remettar.
English: Advocate should not be used in dogs classified as Class 4 for heartworm disease.
Maltese: Advocate m'għandux jintuża fi klieb li huma kklassifikati bħala Klassi 4 għall-marda tad-dud fil-qalb.
English: • for the prevention and treatment of skin worm (infection with Dirofilaria repens) in dogs;
Maltese: • għall-prevenzjoni u l-kura tad-dud tal-ġilda (infezzjoni bid-Dirofilaria repens) fil-klieb;
English: • for the treatment of infections with certain gastrointestinal roundworms, hookworms and whipworms in cats and dogs.
Maltese: • għall-kura ta' infezzjonijiet b'ċertu dud tond gastrointestinali (roundworms), dud forma ta' sunnara
English: Moxidectin causes paralysis and death of parasites by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites' nervous system.
Maltese: Il-mossidektina tikkawża l-paraliżi u l-mewt ta' dawn il-parassiti billi tinterferixxi mal-mod kif is-sinjali jgħaddu bejn iċ-ċelloli tan-nervituri (newrotrażmissjoni) fis-sistema nervuża tal-parassiti.
English: Imidacloprid interferes with certain specific receptors (nicotinergic acetylcholine receptors) in the nervous systems of lice and fleas, which results in their subsequent paralysis and death.
Maltese: L-imidakloprid tinterferixxi ma' ċerti riċetturi speċifiċi (riċetturi nikotinerġiċi tal-aċetilkolinanicotinergic acetylcholine receptors) fis-sistemi nervużi tal-furrax u tal-briegħed u dan iwassal għallparaliżi u l-mewt sussegwenti tagħhom.
English: Although no side effects have been confirmed in ferrets, similar side effects could occur rarely.
Maltese: Minkejja li l-ebda effett sekondarju ma ġie kkonfermat fl-inmsa, f'każijiet rari, jistgħu jseħħu effetti sekondarji simili.
English: The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided.
Maltese: Is-solvent f'Advocate jista' jtebba' jew jagħmel ħsara lil ċerti materjali inklużi ġilda, tessuti, plastiks u wċuħ lesti, għalhekk għandu jiġi evitat kuntatt bejn il-prodott u dawn l-uċuħ.
English: • for the prevention of spirocercosis (a worm infection affecting the gullet) in dogs;
Maltese: • għall-prevenzjoni ta' spiroċerjożi (infezzjoni tad-dud li taffettwa l-esofagu) fil-klieb;
English: Advocate comes in different strengths and different pipette sizes depending on whether it is for use on cats, ferrets or dogs.
Maltese: Advocate jiġi f'qawwiet differenti u f'pipetti ta' daqs differenti skont jekk jintużax fuq il-qtates, l-inmsa jew fuq il-klieb.
English: • for the treatment of notoedric mange in cats;
Maltese: • għall-kura tal-infestazzjonijiet tad-dud fil-widnejn fil-klieb u l-qtates;
English: Date of last renewal: 16 December 2008
Maltese: Data tal-aħħar tiġdid: 16 ta' Diċembru, 2008
English: Progressive scarring of lung tissue (interstitial lung disease)**.
Maltese: Ċikatriċi progressivi ta' tessut tal-pulmun (mard interstizjali tal-pulmun)**
English: Kinzalmono contains sorbitol.
Maltese: Kinzalmono fih sorbitol.
English: 14 tablets 28 tablets 56 tablets 98 tablets 28 x 1 tablets
Maltese: 14-il pillola 28 pillola 56 pillola 98 pillola 28 x 1 pilloli
English: Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000)
Maltese: Ir-reazzjonijiet avversi ġew ikklassifikati skond kategoriji ta' frekwenza bl-użu tal-konvenzjoni li ġejja: komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000), rari ħafna (<1/10,000).
English: One blister contains 7 tablets.
Maltese: Folja waħda fiha 7 pilloli.
English: Do not take Kinzalmono
Maltese: Tiħux Kinzalmono
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 December 1998
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 16 ta' Diċembru, 1998
English: INFORMATION IN BRAILLE Kinzalmono 40 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Kinzalmono 40 mg
English: INFORMATION IN BRAILLE Kinzalmono 20 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Kinzalmono 20 mg
English: INFORMATION IN BRAILLE Kinzalmono 80 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Kinzalmono 80 mg
English: Kinzalmono 40 mg tablets
Maltese: Kinzalmono 40 mg pilloli
English: Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets.
Maltese: Kinzalmono hu disponibbli f'pakketti b'folji ta' 14, 28, 56 u 98 pillola.
English: • Elevated potassium levels in your blood.
Maltese: • Livelli għolja ta' potassium fid-demm tiegħek.
English: The concomitant use of Kinzalmono with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Maltese: L-użu fl-istess ħin ta' Kinzalmono flimkien ma' prodotti li fihom aliskiren huwa kontraindikat f'pazjenti b'dijabete mellitus jew b'indeboliment tal-kliewi (GFR < 60 ml/min/1.73 m2) (ara sezzjonijiet 4.5, u 5.1).
English: Possible side effects of Kinzalmono
Maltese: Effetti sekondarji possibbli ta' Kinzalmono
English: Patients with rare hereditary problems of fructose intolerance should not take Kinzalmono.
Maltese: Pazjenti li għandhom problemi ereditarji rari ta' intolleranza għall-fructose m'għandhomx jieħdu Kinzalmono.
English: Kinzalmono 80 mg tablets
Maltese: Kinzalmono 80 mg pilloli
English: Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets.
Maltese: Kinzalmono hu disponibbli f'pakketti b'folji ta' 14, 28, 56 u 98 pillola jew pakketti bil-folji bid-doża tal-unità li fihom 28 x 1 pilloli.
English: Kinzalmono 40 mg and 80 mg tablets 4 years
Maltese: Kinzalmono 40 mg u 80 mg pilloli 4 snin
English: • If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Kinzalmono” and “Warnings and precautions”).
Maltese: • Jekk qed tieħu inibitur ta' ACE jew aliskiren (ara wkoll l-informazzjoni taħt l-intestaturi “Tiħux Kinzalmono” u “Twissijiet u prekawzjonijiet”).
English: Kinzalmono 20 mg tablets
Maltese: Kinzalmono 20 mg pilloli
English: Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased
Maltese: Tnaqqis fl-emoglobina, żieda fil-uric acid fid-demm, żieda fl enzimi epatiċi, żieda fil-creatine phosphokinase fid-demm
English: Kinzalmono 20 mg tablets EU/1/98/091/009 (14 tablets) EU/1/98/091/010 (28 tablets) EU/1/98/091/011 (56 tablets) EU/1/98/091/012 (98 tablets)
Maltese: Kinzalmono 20 mg pilloli EU/1/98/091/009 (14-il pillola) EU/1/98/091/010 (28 pillola) EU/1/98/091/011 (56 pillola) EU/1/98/091/012 (98 pillola)
English: EU/1/98/091/001 EU/1/98/091/002 EU/1/98/091/003 EU/1/98/091/004 EU/1/98/091/013
Maltese: EU/1/98/091/001 EU/1/98/091/002 EU/1/98/091/003 EU/1/98/091/004
English: • Diabetes.
Maltese: • Dijabete.
English: Other medicines and Kinzalmono
Maltese: Mediċini oħra u Kinzalmono
English: Kinzalmono 40 mg tablets EU/1/98/091/001 (14 tablets) EU/1/98/091/002 (28 tablets) EU/1/98/091/003 (56 tablets) EU/1/98/091/004 (98 tablets) EU/1/98/091/013 (28 x 1 tablets)
Maltese: Kinzalmono 40 mg pilloli EU/1/98/091/001 (14-il pillola) EU/1/98/091/002 (28 pillola) EU/1/98/091/003 (56 pillola) EU/1/98/091/004 (98 pillola) EU/1/98/091/013 (28 x 1 pillola)
English: Kinzalmono is contraindicated in patients with severe hepatic impairment (see section 4.3).
Maltese: Kinzalmono hu kontraindikat f'pazjenti b'indeboliment serju tal-fwied (ara sezzjoni 4.3).
English: The overall incidence of adverse reactions reported with telmisartan (was usually comparable to placebo (41.4 % vs 43.9 %) in controlled trials in patients treated for hypertension.
Maltese: L-inċidenza ta' reazzjonijiet avversi rrappurtati kienet ġeneralment komparabbli mal-plaċebo (41.4% vs 43.9%) fil-provi kkontrollati f'pazjenti kkurati għal pressjoni għolja.
English: See also information under the heading “Do not take Kinzalmono”.
Maltese: Ara wkoll l-informazzjoni taħt t-titlu “Tiħux Kinzalmono”.
English: Kinzalmono 80 mg tablets EU/1/98/091/005 (14 tablets) EU/1/98/091/006 (28 tablets) EU/1/98/091/007 (56 tablets) EU/1/98/091/008 (98 tablets) EU/1/98/091/014 (28 x 1 tablets)
Maltese: Kinzalmono 80 mg pilloli EU/1/98/091/005 (14-il pillola) EU/1/98/091/006 (28 pillola) EU/1/98/091/007 (56 pillola) EU/1/98/091/008 (98 pillola) EU/1/98/091/014 (28 x 1 pillola)
English: At the beginning of the preventive therapy with Kinzalmono 80 mg, blood pressure should be frequently monitored.
Maltese: Fil-bidu tat-terapija preventiva b'Kinzalmono 80mg, il-pressjoni tad-demm għandha tiġi mmonitorjata ta' spiss.
English: Kinzalmono 20 mg tablets 3 years
Maltese: Kinzalmono 20 mg pilloli 3 snin
English: EU/1/98/091/009 EU/1/98/091/010 EU/1/98/091/011 EU/1/98/091/012
Maltese: EU/1/98/091/011 EU/1/98/091/012
English: Kinzalmono 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side.
Maltese: Pilloli bojod ta' 3.8 mm b'forma oblunga li fuqhom hemm imnaqqax in-numru tal-kodiċi ‘51H' fuq naħa waħda.
English: As with other medicinal products acting on the renin-angiotensin-aldosterone-system, telmisartan may provoke hyperkalaemia (see section 4.4).
Maltese: Bħal prodotti mediċinali oħrajn li jaġixxu fuq is-sistema renin-angiotensin-aldosterone, telmisartan jista' jikkawża l-iperkalemija (ara sezzjoni 4.4).
English: Kinzalmono 80 mg tablets White oblong tablets of 4.6 mm engraved with the code number '52H' on one side.
Maltese: Il-pilloli Kinzalmono 80 mg huma bojod, b'forma oblunga u mnaqqxa bin-numru tal-kodiċi ‘52H' fuq naħa waħda.
English: What Kinzalmono looks like and contents of the pack Kinzalmono 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side.
Maltese: Kif jidher Kinzalmono u l-kontenut tal-pakkett Il-pilloli Kinzalmono 20 mg huma bojod, b'forma tonda u mnaqqxa bin-numru tal-kodiċi ‘50H' fuq naħa waħda u l-logo tal-kumpanija fuq in-naħa l-oħra.
English: Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), severe allergic reaction (anaphylactic reaction), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), upset stomach, dry mouth, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
Maltese: Sepsis* (ta' spiss imsejħa "avvelenament tad-demm", hi infezzjoni severa b'rispons infjammatorju mal-ġisem kollu li tista' twassal għal mewt), żieda f'ċerti ċelluli bojod tad-demm (eosinofilija), għadd baxx ta' plejtlits (tromboċitopenja), reazzjoni allerġika severa (reazzjoni anafilattika), reazzjoni allerġika (eż. raxx, ħakk, diffikultà biex tieħu n-nifs, tħarħir, nefħa tal-wiċċ jew pressjoni tad-demm baxxa), livelli baxxi ta' zokkor fid-demm (f'pazjenti dijabetiċi, tħossok ansjuż/a, ngħas, indeboliment fil-vista, rata mgħaġġla ta' taħbit tal-qalb (takikardija), ħalq xott, stonku mqalleb, disturb fit-togħma (tibdil fis-sens tat-togħma), funzjoni anormali tal-fwied (hemm aktar ċans li pazjenti Ġappuniżi jkollhom dan l-effett sekondarju), nefħa mgħaġġla tal-ġilda u tal-mukuża li tista wkoll twassal għal mewt (anġjoedema wkoll b'riżultat fatali), ekżema (disturb tal-ġilda), ħmura tal-ġilda, urtikarja (ħorriqija), raxx sever minħabba l-mediċina, uġigħ fil-gogi (artralġja), uġigħ fl-estremitajiet, uġigħ fittendini, mard li jixbah l-influwenza, tnaqqis fl-emoglobina (proteina fid-demm), żieda fil-livelli taluric acid, żieda fl-enzimi epatiċi jew ta' creatine phosphokinase fid-demm.
English: The main risk factors for hyperkalaemia to be considered are: - Diabetes mellitus, renal impairment, age (>70 years) - Combination with one or more other medicinal products that affect the renin-angiotensinaldosterone system and/or potassium supplements.
Maltese: - Dijabete mellitus, indeboliment renali, età (>70 sena) - Kumbinazzjoni ma' prodott mediċinali wieħed jew aktar li jaffettwaw is-sistema reninangiotensin-aldosterone u/jew is-supplimenti tal-potassium.
English: Kinzalmono belongs to a class of medicines known as angiotensin II receptor antagonists.
Maltese: TWISSIJA SPEĊJALI LI L-PRODOTT MEDIĊINALI GĦANDU JINŻAMM
English: What Kinzalmono looks like and contents of the pack Kinzalmono 40 mg tablets are white, oblong-shaped and engraved with the code number '51H' on one side.
Maltese: Il-pilloli Kinzalmono 40 mg huma bojod, b'forma oblunga u mnaqqxa bin-numru tal-kodiċi ‘51H' fuq naħa waħda.
English: The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non-steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Maltese: Ir-riskju jista' jiżdied f'każ li l-kura tingħata flimkien ma' prodotti mediċinali oħra li jistgħu jikkawżaw ukoll l-iperkalemija (sostituti tal-melħ li fihom ilpotassium, dijuretiċi li ma jneħħux potassium, inibituri ta' ACE, antagonisti tar-riċettur ta' angiotensin II, prodotti mediċinali mhux sterojdi kontra l-infjammazzjoni (NSAIDs, li jinkludu inibituri COX-2 selettivi), eparina, immunosoppressuri (cyclosporin jew tacrolimus), u trimethoprim).